NasdaqGS - Delayed Quote USD

Nanobiotix S.A. (NBTX)

5.41

-0.09

(-1.64%)

At close: 4:00 PM EDT

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CESTPARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023,

GlobeNewswire yesterday

NBTX
-1.64%
11 Best Nanotechnology Stocks To Invest In

In this piece, we will take a look at the 11 best nanotechnology stocks to invest in. If you want to skip our introduction to the nanotechnology sector and how it covers a variety of applications ranging from healthcare to consumer technology, then you can skip ahead to read 5 Best Nanotechnology Stocks To Invest […]

Insider Monkey 6 days ago

NANO.PA

TSM

SNPS
Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights, exercisabl

GlobeNewswire 8 days ago

NBTX
-1.64%
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapyConfirmation of injection feasibility and favorable safety profile in completed Phase 1 dose escalation part of the study support potential for later stage development of NBTXR3 for the treatment of patients with inoperable, recurrent NSCLC who are amenable to re-irradiationThe dose expansion part of

GlobeNewswire 16 days ago

NBTX
-1.64%
Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event. Leerink P

GlobeNewswire last month

NBTX
-1.64%
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on

GlobeNewswire 2 months ago

NBTX
-1.64%
Baillie Gifford Bolsters Stake in Nanobiotix SA

Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. This transaction was executed at a trade price of $5.81 per share, reflecting a 48.18% change in the firm's holdings and a 6.21% ownership in Nanobiotix SA. Despite the significant addition, the trade had a negligible impact on Baillie Gifford (Trades, Portfolio)'s portfolio, with the position accounting for just 0.02% of its total investments.

GuruFocus.com 2 months ago

NBTX
-1.64%
^YH103
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M mile

GlobeNewswire 2 months ago

NBTX
-1.64%
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize

GlobeNewswire 3 months ago

NBTX
-1.64%
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

GlobeNewswire 4 months ago

NBTX
-1.64%
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial designPromising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local disease con

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ETPARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, a

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX Announces Closing of Global Offering

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordina

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

NBTXR3-RT + anti-PD-1 NBTXR3-RT + anti-PD-1: ongoing discussions at Nanobiotix relating to this potential study in recurrent and/or metastatic head and neck cancers under consultation prior to continuing discussions with the FDA with the perspective of establishing a protocol for a pivotal study PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-ba

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing o

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering (representing approximately €28.4 million) reserved to specified categories of investors consisting

GlobeNewswire 5 months ago

NBTX
-1.64%
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose23 months median Overall Survival (mOS) observed in 17 patients treated with cytotoxic chemotherapy followed by RT-activated NBTXR3 Review of an historical control from the same center as this Phase 1 in 243 patients with LAPC showed an mOS of 19.2 months in 144 patients who rec

GlobeNewswire 5 months ago

NBTX
-1.64%
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society for Radiation Oncology Waterfall Plot Best Observed Response in Injected Lesions Based on Investigator Assessment Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently

GlobeNewswire 6 months ago

NBTX
-1.64%
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dos

GlobeNewswire 6 months ago

NBTX
-1.64%
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a tolerable safety profile in 15 patientsAs of the data cutoff, in 13 patients evaluable for efficacy, the study showed an injected tumor disease control rate of 92.3% (12/13)Preliminary results from the ongoing study showed median overall survival of 21 months from diag

GlobeNewswire 6 months ago

NBTX
-1.64%

Performance Overview

Return	NBTX	CAC 40
YTD	-25.69%	+6.35%
1-Year	+36.96%	+6.49%
3-Year	-66.97%	+27.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nanobiotix S.A. (NBTX)

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

11 Best Nanotechnology Stocks To Invest In

Voting Rights and Shares Capital of the Company

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Nanobiotix to Present at Upcoming Investor Conferences in March

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Baillie Gifford Bolsters Stake in Nanobiotix SA

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

NANOBIOTIX Announces Closing of Global Offering

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Performance Overview